[Use of posaconazole in children: Experience in a tertiary pediatric hospital].
- Resource Type
- Academic Journal
- Authors
- Rosanova MT; Servicio de Control Epidemiológico e Infectología, Hospital 'Prof. Dr. Juan P. Garrahan', Ciudad Autónoma de Buenos Aires, Argentina. margris2@yahoo.com.ar.; Voto C; Servicio de Control Epidemiológico e Infectología, Hospital 'Prof. Dr. Juan P. Garrahan', Ciudad Autónoma de Buenos Aires, Argentina.; Mussini MS; Servicio de Control Epidemiológico e Infectología, Hospital 'Prof. Dr. Juan P. Garrahan', Ciudad Autónoma de Buenos Aires, Argentina.; Sarkis C; Servicio de Control Epidemiológico e Infectología, Hospital 'Prof. Dr. Juan P. Garrahan', Ciudad Autónoma de Buenos Aires, Argentina.; Gómez S; Servicio de Control Epidemiológico e Infectología, Hospital 'Prof. Dr. Juan P. Garrahan', Ciudad Autónoma de Buenos Aires, Argentina.; Sberna N; Servicio de Farmacia, Hospital 'Prof. Dr. Juan P. Garrahan', Ciudad Autónoma de Buenos Aires, Argentina.; Carnovale S; Servicio de Micología, Hospital 'Prof. Dr. Juan P. Garrahan', Ciudad Autónoma de Buenos Aires, Argentina.; Caracciolo B; Servicio de Micología, Hospital 'Prof. Dr. Juan P. Garrahan', Ciudad Autónoma de Buenos Aires, Argentina.; Lede R; Universidad Abierta Interamericana (UAI), Buenos Aires, Argentina.
- Source
- Publisher: Sociedad Argentina de Pediatría Country of Publication: Argentina NLM ID: 0372460 Publication Model: Print Cited Medium: Internet ISSN: 1668-3501 (Electronic) Linking ISSN: 03250075 NLM ISO Abbreviation: Arch Argent Pediatr Subsets: MEDLINE
- Subject
- Language
- Spanish; Castilian
There is limited information on the use of posaconazole in children. This retrospective and descriptive study was conducted to evaluate the clinical, microbiological characteristics and evolution of patients treated with posaconazole between August 2010 and March 2017. We included 16 children. Median age: 161 months (interquartile range -IQR- 69-173 m). All had underlying disease and a proven invasive fungal infection. The most frequent isolated were Mucor spp. and Aspergillus spp. The mean posaconazole dose was 600 mg/day (400-800 mg/day) and the median duration of treatment was 223 days (IQR 48-632). Ten patients had adverse effects, but only one required suspension of the antifungal treatment due to hydroelectrolytic disorders.
(Sociedad Argentina de Pediatría.)